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BACKGROUND & AIMS: Several models have been used to determine prognoses of patients with
alcoholic hepatitis. These include static systems (the Maddrey discriminant function; age, bilirubin,
international normalized ratio, creatinine [ABIC] score; and model for end-stage liver disease [MELD]
score) and dynamic models (the Lille model). We aimed to combine features of all of these models to
develop a better method to predict outcomes of patients with alcoholic hepatitis.
METHODS: We collected data from several databases of patients with severe alcoholic hepatitis
treated with corticosteroids in France and the United Kingdom to create a model to predict patient
survival (derivation cohort, n = 538 patients). We compared the performances of 3 joint-effect models
(Maddrey+Lille, MELD+Lille, and ABIC+Lille) to determine which combination had the best
prognostic value, based on known patient outcomes. The model was validated using data from trials
of the effects of corticosteroids in patients in the United States, France, Korea, and Belgium (n = 604
patients).
RESULTS: We created a joint-effect model to predict patient survival after 2 and 6 months; in the
derivation and validation cohorts it predicted outcome significantly better than either static or
dynamic models alone (P < .01 for all comparisons). The joint model accurately predicted patient
survival regardless of patient risk level. The MELD+Lille combination was better than the
Maddrey+Lille or ABIC+Lille combination in predicting patient survival, with Akaike information
criterion values of 1305, 1313, and 1312, respectively. For example, based on the MELD+Lille
combination model, the predicted 6-month mortality of complete responders with MELD scores of
15-45 (Lille score, 0.16) was 8.5% to 49.7%, compared with 16.4%-75.2% for nonresponders (Lille
score, 0.45). According to the joint-effect model, for 2 patients with the same baseline MELD score of
21, the patient with a Lille score of 0.45 had a 1.9-fold higher risk of death than the patient with a
Lille score of 0.16 (23.7% vs 12.5%).
CONCLUSIONS: By combining results from static and dynamic scoring systems for liver disease, we
can better predict outcomes of patients with alcoholic hepatitis, compared with either model alone.
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